Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB)

OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology

(2013) David Ginsberg et al.   ADVANCES IN THERAPY

Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox®) or abobotulinumtoxinA (Dysport®) make a difference?

(2013) Pravisha Ravindra et al.   BJU INTERNATIONAL

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

(2013) Christopher Chapple et al.   EUROPEAN UROLOGY

An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders

(2013) Altaf Mangera et al.   EUROPEAN UROLOGY

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

(2013) M. B. Chancellor et al.   NEUROLOGY

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity

(2013) Eric Rovner et al.   NEUROUROLOGY AND URODYNAMICS

Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis

(2013) Michael Kennelly et al.   UROLOGY

Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity

(2012) David Ginsberg et al.   JOURNAL OF UROLOGY

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Urinary incontinence in children: botulinum toxin is a safe and effective treatment option

(2012) Dermot Thomas McDowell et al.   PEDIATRIC SURGERY INTERNATIONAL

Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay

(2012) Ester Fernández-Salas et al.   PLoS One

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

(2011) Francisco Cruz et al.   EUROPEAN UROLOGY

Prospective Randomised Controlled Trial Comparing Trigone-Sparing versus Trigone-Including Intradetrusor Injection of AbobotulinumtoxinA for Refractory Idiopathic Detrusor Overactivity

(2011) Rustom P. Manecksha et al.   EUROPEAN UROLOGY

Efficacy and Tolerability of Botulinum Toxin Type A in Patients with Neurogenic Detrusor Overactivity and Without Concomitant Anticholinergic Therapy: Comparison of Two Doses

(2010) Philippe Grise et al.   EUROPEAN UROLOGY

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

(2010) Roger Dmochowski et al.   JOURNAL OF UROLOGY